|
Commitments and Contingencies - Additional Information (Detail) (USD $)
|
1 Months Ended | 12 Months Ended | 0 Months Ended | 1 Months Ended | 12 Months Ended | 12 Months Ended | 12 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Oct. 31, 2012
|
May 31, 2014
|
May 31, 2013
|
May 31, 2014
Progenics Pharmaceuticals, Inc
|
Jan. 20, 2014
Project Work Order
Project
|
Dec. 31, 2013
Project Work Order
|
May 31, 2014
Project Work Order
|
May 31, 2014
Project Work Order
One Study
|
May 31, 2014
Project Work Order
Amarex Clinical Research, LLC
|
May 31, 2014
Initial Payment
|
May 31, 2014
Milestone Payments
US Phase III trial
|
May 31, 2014
Milestone Payments
US new drug application approval by the FDA
|
May 31, 2014
Development Milestone Payments
|
May 31, 2014
Development Milestone Payments
US Phase III trial
|
May 31, 2014
Development Milestone Payments
US new drug application approval by the FDA
|
May 31, 2014
Development Milestone Payments
New Drug Application with the FDA
|
May 31, 2014
Director
|
May 31, 2014
Director
Stock Option Award Agreement dated Dec 6,2010
|
May 31, 2014
Director
Stock Option Award Agreement dated September 22,2010
|
May 31, 2014
Director
Stock Option Award Agreement dated April 16,2012
|
|
| Commitment And Contingencies [Line Items] | ||||||||||||||||||||
| Salary | $ 13,890 | |||||||||||||||||||
| Cash severance payment | 13,890 | |||||||||||||||||||
| Severance period | 33 months | |||||||||||||||||||
| Reimbursement of health insurance period | 9 months | |||||||||||||||||||
| Stock option award agreement | 500,000 | 750,000 | ||||||||||||||||||
| Stock Option granted, per share | $ 1.19 | $ 2.00 | ||||||||||||||||||
| Options granted | 25,000 | |||||||||||||||||||
| Option immediate vesting | 50,000 | 780,000 | 1,500,000 | |||||||||||||||||
| Options forfeiture | 750,000 | |||||||||||||||||||
| Severance expense | 172,000 | |||||||||||||||||||
| Severance liabilities | 193,000 | |||||||||||||||||||
| Stock based compensation expense | 1,128,000 | |||||||||||||||||||
| Asset purchase, cash paid | 3,500,000 | 3,500,000 | 1,500,000 | 5,000,000 | 1,000,000 | 500,000 | 500,000 | |||||||||||||
| Royalty on every net sales | 5.00% | 7.50% | ||||||||||||||||||
| Asset Purchase Agreement Aggregate Consideration Paying Period | 10 years | 10 years | ||||||||||||||||||
| Minimum annual license maintenance fees | 150,000 | |||||||||||||||||||
| Number of research studies projects | 2 | |||||||||||||||||||
| Number of projects terminated | 1 | |||||||||||||||||||
| Project termination notice period | 30 days | |||||||||||||||||||
| Estimated combined cost of two separate studies | 9,300,000 | |||||||||||||||||||
| Estimated cost terminated without penalty | 4,300,000 | |||||||||||||||||||
| Estimated remaining cost | 3,700,000 | 1,000,000 | ||||||||||||||||||
| Payment to CRO for deposit | 790,000 | |||||||||||||||||||
| Termination period upon prior notice | 30 days | |||||||||||||||||||
| Percentage of remaining contract amount for direct services to be paid upon termination | 30.00% | |||||||||||||||||||
| Postponed research studies amounts allowed to be applied to all amounts due to the CRO | $ 343,000 | |||||||||||||||||||